Literature DB >> 19465733

Patellofemoral full-thickness chondral defects treated with second-generation autologous chondrocyte implantation: results at 5 years' follow-up.

Alberto Gobbi1, Elizaveta Kon, Massimo Berruto, Giuseppe Filardo, Marco Delcogliano, Lorenzo Boldrini, Lyndon Bathan, Maurilio Marcacci.   

Abstract

BACKGROUND: Patellofemoral lesions represent a very troublesome condition to treat for orthopaedic surgeons; however, second-generation autologous chondrocyte implantation (ACI) seems to offer an interesting treatment option with satisfactory results at short-term follow-up. HYPOTHESIS: Hyaluronan-based scaffold seeded with autologous chondrocytes is a viable treatment for the damaged articular surface of the patellofemoral joint. STUDY
DESIGN: Case series; Level of evidence, 4.
METHODS: Among a group of 38 patients treated for full-thickness patellofemoral chondral lesions with second-generation ACI, we investigated 34 who were available for final follow-up at 5 years. These 34 had chondral lesions with a mean size of 4.45 cm(2). Twenty-one lesions were located on the patella, 9 on the trochlea, and 4 patients had multiple lesions: 3 had patellar and trochlear lesions, and 1 had patellar and lateral femoral condyle lesions. Twenty-six lesions (76.47%) were classified as International Cartilage Repair Society (ICRS) grade IV A or B, 5 lesions (14.70%) were grade IIIC, and 3 (8.82%) were lesions secondary to osteochondritis dissecans (OCD). Results were evaluated using the International Knee Documentation Committee (IKDC) 2000 subjective and objective scores, EuroQol (EQ) visual analog scale (VAS), and Tegner scores at 2 and 5 years. Eight patients had second-look arthroscopy and biopsies.
RESULTS: All the scores used demonstrated a statistically significant improvement (P < .0005) at 2 and 5 years' follow-up. Objective preoperative data improved from 8 of 34 (23.52%) normal or nearly normal knees to 32 of 34 (94.12%) at 2 years and 31 of 34 (91.17%) at 5 years after transplantation. Mean subjective scores improved from 46.09 points preoperatively to 77.06 points 2 years after implantation and 70.39 at 5 years. The Tegner score improved from 2.56 to 4.94 and 4.68, and the EQ VAS improved from 56.76 to 81.47 and 78.23 at 2 and 5 years' follow-up, respectively. A significant decline of IKDC subjective and Tegner scores was found in patients with multiple and patellar lesions from 2 to 5 years' follow-up. Second-look arthroscopies in 8 cases revealed the repaired surface to be nearly normal with biopsy samples characterized as hyaline-like in appearance.
CONCLUSION: Hyaluronan-based scaffold seeded with autologous chondrocytes can be a viable treatment for patellofemoral chondral lesions.

Entities:  

Mesh:

Year:  2009        PMID: 19465733     DOI: 10.1177/0363546509331419

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  49 in total

Review 1.  The use of the Tegner Activity Scale for articular cartilage repair of the knee: a systematic review.

Authors:  Karen Hambly
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2010-11-13       Impact factor: 4.342

2.  ... more bricks to the building of cartilage knowledge?

Authors:  Mats Brittberg
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2009-11       Impact factor: 4.342

Review 3.  The current state of scaffolds for musculoskeletal regenerative applications.

Authors:  Benjamin D Smith; Daniel A Grande
Journal:  Nat Rev Rheumatol       Date:  2015-03-17       Impact factor: 20.543

4.  Bioinspired Scaffold Designs for Regenerating Musculoskeletal Tissue Interfaces.

Authors:  Mohammed A Barajaa; Lakshmi S Nair; Cato T Laurencin
Journal:  Regen Eng Transl Med       Date:  2019-12-17

5.  [Post-treatment rehabilitation after autologous chondrocyte implantation: State of the art and recommendations of the Clinical Tissue Regeneration Study Group of the German Society for Accident Surgery and the German Society for Orthopedics and Orthopedic Surgery].

Authors:  M F Pietschmann; A Horng; C Glaser; D Albrecht; J Bruns; S Scheffler; S Marlovits; P Angele; M Aurich; U Bosch; J Fritz; K H Frosch; T Kolombe; W Richter; J P Petersen; U Nöth; P Niemeyer; M Jagodzinsky; P Kasten; K Ruhnau; P E Müller
Journal:  Unfallchirurg       Date:  2014-03       Impact factor: 1.000

6.  Cell-based therapy improves function in adolescents and young adults with patellar osteochondritis dissecans.

Authors:  Bryon J X Teo; Kizher Buhary; Bee-Choo Tai; James H Hui
Journal:  Clin Orthop Relat Res       Date:  2013-04       Impact factor: 4.176

7.  Matrix-induced autologous chondrocyte implantation (MACI) for chondral defects in the patellofemoral joint.

Authors:  Daniel Meyerkort; Jay R Ebert; Timothy R Ackland; William B Robertson; Michael Fallon; M H Zheng; David J Wood
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-05-11       Impact factor: 4.342

8.  Fresh Osteochondral Allograft Transplantation for Fractures of the Knee.

Authors:  Guilherme C Gracitelli; Luis Eduardo Passarelli Tirico; Julie C McCauley; Pamela A Pulido; William D Bugbee
Journal:  Cartilage       Date:  2016-07-07       Impact factor: 4.634

9.  Autologous Chondrocyte Implantation to Isolated Patella Cartilage Defects.

Authors:  Arvind von Keudell; Roger Han; Tim Bryant; Tom Minas
Journal:  Cartilage       Date:  2016-07-08       Impact factor: 4.634

10.  Next Generation Mesenchymal Stem Cell (MSC)-Based Cartilage Repair Using Scaffold-Free Tissue Engineered Constructs Generated with Synovial Mesenchymal Stem Cells.

Authors:  Kazunori Shimomura; Wataru Ando; Yu Moriguchi; Norihiko Sugita; Yukihiko Yasui; Kota Koizumi; Hiromichi Fujie; David A Hart; Hideki Yoshikawa; Norimasa Nakamura
Journal:  Cartilage       Date:  2015-03-24       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.